Admescope provides the pharmaceutical, biotechnology and veterinary industry tailor made nonclinical ADME-Tox services. Our service offering covers research services for peptides, biologics and small molecules and is widely spread over the whole ADME-Tox area. The right assays are available, whether in the discovery or lead optimisation phase. The level of data interpretation can be customized according to customer preferences. Currently, Admescope has customers in 29 countries on 4 continents.
Understanding the causal mechanisms of a disease is the necessary step to find the most adapted solutions and effective biomarkers are our objectives.
With our proprietary CADI™ Discovery analytical platform, BMSystems’ team generates novel, fully informed, disruptive concepts from scientific, medical & health data, providing new diagnostic, therapeutic and prevention solutions for medicine.
With BioConnection you have access to aseptic production of small-scale clinical batches, filling and freeze-drying as well as 250L scale production of commercial batches. All under one roof and EMA and US-FDA certified.
Biogazelle is a CRO specialized in high-value applications to support pharmaceutical research, clinical trials and diagnostic test development. We hold a unique position in the application of quantitative PCR, digital PCR and RNA sequencing workflows optimized for analyzing coding and non-coding genes, on valuable clinical samples such as liquid biopsies or FFPE tissues. We aim to speed up the development of therapeutics, such as small molecules, RNA targeted drugs, and adoptive cell therapies.
Biogenouest provide advanced research facilities to the scientific community in western France. We combine expertise, capability and equipment through a network. Our team all strive to develop state-of-the-art technology platforms drawing on a coordinated approach. Our network brings together 34 technology core facilities that deliver hands-on solutions for labs and businesses across: genomics, proteomics, functional exploration, bioimaging structural and metabolic analysis, and bioinformatics.
CARBOGEN AMCIS leverages world-class chemistry skills to provide drug development and commercialization services to pharmaceutical and biopharmaceutical companies. Our cGMPcompliant
infrastructure includes dedicated Highly Potent facilities and a clean room for Antibody Drug Conjugates. We also offer high-quality Cholesterol and Vitamin D analogs. Learn more at www.carbogen-amcis.com
Clubster NHL – Nutrition, Health, Longevity – is a French competitiveness cluster federating 350 members in the Nutrition, biotechnology and health sectors. We foster collaboration between academia, private companies (start-up, SMEs and large companies), clinicians and final users. Our aim is to help our members to design, develop and finance their innovative products and processes. The activity encompasses the ONE HEALTH concept, close relation between human, animal and plant health.
CRYOPDP is the first choice courier for Life Sciences and Healthcare industries with more than 25 years of experience. Which has as its mission to improve the health of people around the world by providing global innovative temperature-controlled logistics solutions to the Clinical Research and Cell & Gene Therapy communities.
Set up on 1st January 2000, EFS is the only public blood transfusion organization in France. The core mission of EFS is to ensure national self-sufficiency in blood products under optimal conditions of safety and quality. EFS manages the collection, screening, processing and distribution of labile blood products to health-care establishments.
Beyond its blood transfusion activity, EFS has developed a wide range of activities intended to promote progress for the benefit of patient.
Eurasanté is a development agency dedicated to tech transfer and business development in life sciences sector in Northern France region. Our experienced project managers help researchers, startups and companies with their development projects. To do so, Eurasante provides many services such as real estate, fundraising, recruitment and business development. It also promotes the Eurasante Bio-business Park, which already hosts 8 hospitals, 4 universities, 8 specialised schools and more than 170 companies. It benefits from an exceptional location at the heart of Europe.
Founded in 2009 by regional stakeholders, EUROBIOMED is the Life Science cluster from Southern France. We gather more than 400 innovative biotech and medtech companies, as well as leading research institutes, hospitals and universities. We lead territorial initiatives and help our members businesses and research organisations to innovate, finance, develop and achieve their scientific and business objectives, to ultimately improve the treatment and the lives of patients.
Eurofins CDMO provides integrated, end-to-end development and manufacturing services for Drug Substance/API and Drug Product manufacturing for biologics and small molecules. We are experts for highly potent compounds, poorly soluble drugs, lyophilisation processes, orphan drugs, paediatric forms… Our services: DS Development, Solid State R&D, Preformulation, Formulation Development, GMP Manufacturing, Clinical Packaging and Logistics, CMC Regulatory Support.
Contact us: www.eurofins.com/cdmo
faCellitate specializes in the development of polymer surface coatings for laboratory consumables to create a fully synthetic, biologically relevant environment for cell-based assays. The highly defined and standardized products are used in areas of biomedical research such as cancer and stem cell research, early drug discovery and toxicology to enable and significantly refine the efficiency and predictability of preclinical cell-based models.
"Carnot institute" is label awarded to research centers of excellence which have been able to demonstrate their ability to conduct research projects with industry at highest quality standards. Members of the consortium include Institut Pasteur, Institut Curie, Institut du Cerveau, Institut de la Vision, Institut Imagine (genetic diseases), Institut Calym (lymphoma), INRAE, CEA, ...
IMODE is a collaborative research project for multicomponent pharmaceutical products (co-amorphous and co-crystals) and medical devices that are loaded with bioactive molecules. Started in 2016, the IMODE project is funded by the European Interreg 2 Seas programme and co-financed by the European Regional Development Fund (ERDF).
Founded in 2012, InnoSer is an innovative and dynamic contract research organization (CRO) that supports the discovery and preclinical development of drugs. InnoSer’s offerings include a unique, conditional knockout model for ADPKD (nephrology) in mice, a patient derived screening-platform for oncology: PDX/O, and a first-in-class, validated, midbrain-organoid platform to screen drugs for Parkinson’s disease. Also, InnoSer provides pathology- and in-vivo research services including colony management, cryopreservation, sanitation/rederivation.
In an era of digitalization, Big Data and Data Science, data is a major part of every company. For the Life Sciences, data management is critical.
Our duty is to go with every company improving their information system, handling, hosting, and processing their data processing with quality assurance.
Our services are focused on 3 main expertise: Data Compliance, Data to Information and Data Hosting. Each service follows Life Sciences regulations and professional recommendations.
RD-BIOTECH: French CRO. Custom services: development and production of plasmid, monoclonal antibody, recombinant protein and antibody (Fab, scFv...). Analytical platform for QC & proteins characterization.
DIACLONE: Product portfolio: mAbs (Cytokins, CD markers…), ELISA, ELISpot, SARS-CoV-2 products. Antibody development (hybridoma & phage display) & bioassays services
QVQ: VHH custom development & products
SYNABS: Anti-species secondary antibodies & mAb development (expert for small target)
Materia Nova is a technological accelerator of sustainable innovations in the field of new materials and processes. The approach of Materia Nova is based on an open and collaborative innovation.
In the framework of a collaborative Interreg program, we developed a new portable device for early and specific rapid detection of microorganisms. Using DNA or antigenic probes on a plasmonic chip, this device was first dedicated to agriculture applications and is now adapted to biomedical domain.
Ready to consult, design, conduct and submit preclinical studies you need for your product. We are flexible, effective and affordable.
- advanced tox studies supporting phase I – III CT
- expertise in non-rodent (HNP, dogs, pigs, cats, rabbits, ferrets) and rodent tox
- human & veterinary products (small molecules, vaccines, biotech derived, medical device
- revision of study documentation, implementation GLP
- GLP certified 1991
- CIR certified
Our mission is to participate and assist in the development of scientific projects by offering a comprehensive range of techniques and skills to execute the best pathology services. We have experience in preparing and evaluating histologic slides from all sort of tissues and species used in non-clinical research and development. Our objective is to build effective, constructive and trusted, long-term partnerships with our customers.
OncoDiag has fully developped and validated Urodiag, a simple urine test for the surveillance of bladder cancer (NMIBC). It will be on the market in 2021.
Two other tests are in the validation process and should be available in 2022:
- Prostadiag, a test to determine the agressivity level of prostate cancer to help urologists to choose the best treatment and to reduce the number of surgery,
- Colodiag, a simple blood test to screen population for early detection of colorectal cancer.
At the time of a new industrial revolution, we are convinced that if factories must become smart and connected, the men and women remain the beating heart of production activities. To achieve this transformation for all and by all, it is necessary to rethink human-machine-data interactions.
By leveraging intuitive 3D digital twin technologies, we empower biopharmaceutical teams to easily access data and optimize processes from planning and simulation, to operator learning and asset management.
Founded in 2018, Palm'Data is focusing on lifesciences industry (pharmaceutical, cosmetics, medical devices). Our solutions enable us to support our clients with the organization, protection and use of their data, whatever the medium (paper, electronic, samples, biological specimens) in compliance with GxP regulations. Quality is our DNA, and our clients are our number one priority.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. To learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Real Research is a dynamically grown biotechnological start-up founded in 2017 by two enthusiastic founders. To obtain reliable data, Real Research has developed a unique 3D cell culture hydrogel called LifeGel. LifeGel is a technology platform which can be customised to mimic the physiological environment of cancer and various organs. Real Research is collaborating with pharma companies and provides necessary services and knowledge to clients.
The French association for animal health industry (SIMV) represents manufacturers and marketers (on the French market) of medicines and reagents for pets and for farm animals. In order to contribute to the competitiveness of its member companies, the SIMV defines its value creation through its trades:
Representing the positions of its members.
We are commercializing a treatment for a severe form of corneal blindness called limbal stem cell deficiency. This rare disease causes a significant societal burden because it occurs especially in young and working age people. The treatment is based on IP-protected technology for differentiating highly potent limbal stem cells from human pluripotent stem cells, providing an unlimited source of therapeutic cells. Our technology is currently in the preclinical phase.
Synaxys realizes preclinical assays and R&D projects to rapidly predict the response of the human nervous system before starting clinical trials. Using our proprietary 5D-brain models, we propose custom pharmacology and toxicology screens and electrophysiological assays on neural functions to identify the targets and actions of a compound. 5D-brain models are long lived, composed of all the neuronal cell types and bring pertinent data on Epilepsy, Parkinson, Multiple Sclerosis, Autism, Alzheimer
SYNCROSOME is an innovative preclinical CRO with relevant disease models we offer robust drug efficacy data and high value interpretation to assist drug discovery companies in evaluating the potential of their therapeutic compounds. We provide more than 15 predictive animal models of pathology in CNS, cardiovascular, gastroenterology, respiratory and metabolic disorders.
The Syneos Health Translational Science Team consists today of 80+ seasoned Scientist co-located in one site embedded in a Bio-Park in SE France, and works on a Laboratory space of about 2,900 m2, with more than 200 pieces of state-of-the-art equipment. Our sound cumulative expertise of Pharmaceutical Development enables us to have a clear knowledge of pharmaceutical projects, development hurdles and the vision to take into account risks mitigation factors in the sequence for success.
Based in Lille (France) X’PROCHEM is a biotech company with proprietary chemical technology platform, which helps its bio-pharma partners design and create therapeutic, vaccine and diagnostic mid-size proteins. Our vison is to make today’s and tomorrow’s bio-pharmaceuticals better and more accessible.
Xell is an innovative and agile partner for the biotech and pharmaceutical industry, providing highly efficient solutions in cell culture technology. Besides our dedicated focus on cell culture media development, we have also strengthened our proprietary technology.
Successful projects e.g. improving process efficiency, yields and quality in biopharmaceutical production for customers as BeiGene, Boehringer Ingelheim or Sanofi, CMOs SMEs, have helped us gain a reputation as reliable partner.
XPECT-INX® is a spin-off project of Ghent University (Belgium). By developing and offering high quality bioinks and biomaterials, we aim to be your support in bioprinting to bring tissue engineering and regenerative medicine closer to clinical reality! To do so we provide researchers, clinicians and industry the unique tools for break-through research. Please enquire if you require a specific (custom) bioink or biomaterial ink for your application.
Zoetis is currently the leading animal health company globally. We discover, develop, manufacture and commercialize medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals in more than 100 countries.